Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report

RT @biotech_chris: $ADAP Remember that radiation study Adaptimmune carried out a few years back? It looks like it might have worked Durab…

$ADAP Afami-cel #Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T-cell therapy https://t.co/9xqorP7GYJ

$ADAP https://t.co/fkegnq6a5B @Adaptimmune ? $CRSP $EDIT $NTLA $BEAM $SGEN $MGTX $BLUE $QURE $IONS $VRTX $CRIS $ALNY $SRPT $IONS $VYGR $XON $BOLD $ABEO $GBT $RGNX $BMRN $SGRY $BLCM $ATRA $DRNA $AVRO $MDGL $SGRY $IMPL $SGMO $QFIN $BABA $JNJ $PFE $AMGN $LLY

RT @biotech_chris: $ADAP Remember that radiation study Adaptimmune carried out a few years back? It looks like it might have worked Durab…